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A workshop sponsored by the Human Toxicology Project Consortium (HTPC), “Building Shared Experience to 
Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action”
 
brought together experts 
from a wide range of perspectives to inform the process of pathway development and to advance two prototype 
pathways initially developed by the European Commission Joint Research Center (JRC): liver-specific fibrosis and 
steatosis.  The first half of the workshop focused on the theory and practice of pathway development; the second on 
liver disease and the two prototype pathways.  Participants agreed pathway development is extremely useful for 
organizing information and found that focusing the theoretical discussion on a specific AOP is extremely helpful.  In 
addition, it is important to include several perspectives during pathway development, including information specialists, 
pathologists, human health and environmental risk assessors, and chemical and product manufacturers, to ensure 
the biology is well captured and end use is considered.  
 







As part of its activities to further the science of pathway-based approaches to toxicity, the Human Toxicology Project 
Consortium (HTPC) convened a workshop, “Building Shared Experience to Advance Practical Application of 
Pathway-Based Toxicology: Liver Toxicity Mode-of-Action.”
 1
  Goals of the workshop were to inform 1) the process of 
pathway development, 2) the scope of two liver-specific pathways for liver fibrosis and steatosis developed by the 
European Commission Joint Research Center (JRC), and 3) ways in which pathway approaches can be used in 
decision-making processes.  Discussions and presentations were directed at assessing the state-of-the-art in 
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 Workshop held at the Mount Washington Center, Baltimore, MD, January 23-25, 2013; for more information on the Human 
Toxicology Project Consortium, please visit http://www.humantoxicologyproject.org 
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Pathway-based approaches in biology evolved in part to organize the abundance of mechanistic biological data 
generated by new experimental technologies – genomics, proteomics, metabolomics, and reconstructed tissues, for 
example.  Pathway applications to toxicology were recognized and advanced by such programs as the International 
Program on Chemical Safety (IPCS) to determine human relevance of various Mode-of-Action (MoA) pathways 
leading to carcinogenic (Boobis, et al. 2006) and non-carcinogenic (Boobis et al., 2008) toxicity.  In 2007, the National 
Research Council (NRC) further developed the pathway approach with its concept of toxicity pathways (NRC, 2007)– 
normal biological pathways that have been or can be perturbed into toxicity in a way that is both predictable and 
predictive (in part using data generated by the ‘omics technologies mentioned above).  The Organization for 
Economic Co-operation and Development (OECD) Test Guidelines Program has embraced and refined the concept 
of the Adverse Outcome Pathway (AOP) for use in toxicological assessments for human health and ecological 
endpoints and published guidance and a template for development (OECD, 2013) and several AOPs are now under 
development. One of the goals of this workshop was to advance two liver-specific pathways
2
 - one describing liver 
steatosis and the other describing liver fibrosis - while generating principles and ideas that will apply to pathway 
construction and use more broadly.  Further background is provided in the accompanying review, “Building Shared 






3     Pathway-based approaches to toxicology: principles of pathway development  
 
The presentations in this section provided overviews on the development of AOPs, and examples of specific 
applications in risk assessment.  Discussants largely agreed on several key points about the elements and 
approaches necessary for AOP construction: (1) AOPs are extremely useful for organizing information at all levels of 
biological processes (from the molecular, cellular and tissue level to the population-level) and across the spectrum of 
biological information (chemistry, bioinformatics, ‘omics, histology, guideline animal data); (2) while it is useful to 
conceive of the AOP as a linear segment of a biological network that includes a single molecular initiating event (MIE) 
and ending in a single adverse outcome (AO)
5
 this may be too limiting: some AOPs may necessarily involve 
branching and networking (Kleensang et al., 2013); (3) the confidence and completeness of an AOP will determine its 
usefulness: less complete and more qualitative AOPs can be useful for chemical categorization and prioritization of 
chemicals for further testing; as the confidence and quantitative understanding of the links between events increases, 
the AOP becomes increasingly applicable for use in risk assessment; (4) description of key events is a central 
challenge in pathway development; (5) for some participants, the terms Mode-of-Action (MOA) and AOP were 
synonymous and for others, the AOP encompasses the MOA, which is the upstream portion of the AOP, from the 
MIE through to resulting cellular and tissue changes; the need for common terminology was a common refrain; (6) the 
quality assurance methodologies described in OECD guidance (e.g. to assess data quality, causal relationships and 
completeness of the AOP) are appropriate and essential; (7) AOP development should be an iterative and public 
process; (8) the best way to progress is to develop case studies (several groups are taking this approach: for 
example skin sensitization (Mackay et al., 2013); estrogen receptor (Schmieder, Andersen, CAAT), liver cholestasis 
(Vinken et al., 2013), fibrosis and steatoisis (JRC)).  
 
3.1 Adverse Outcome Pathways: their Development and Use – Terry Schultz 
The concept of the Adverse Outcome Pathway evolved from work showing that chemical structure could predict 
biological activity, and was originally intended to inform chemical category formation (by identifying structurally related 
chemicals that have similar biological activities).  AOPs were not originally intended for risk assessment, but, it was 
found that in addition to informing chemical categories, they can be used to inform test guidelines and testing 
strategies. The question at OECD is not “is there going to be a paradigm shift?” but rather “how do we accelerate it?” 
AOPs have therefore become an underlying principle of the OECD Test Guidelines Program to determine the safety 
of chemicals. 
The current testing paradigm is founded on a checklist of standard in vivo tests and is inadequate to meet 
the increased demands for testing imposed by legislative mandates.  This has prompted consideration of alternative 
methods.  But because the predictions generated by these methods are not yet well-explained in terms of mechanism 
or relevance, they are (so far) not widely accepted.  Acceptance is hindered by the fact that most in vivo endpoints 
are not amenable to direct prediction by in silico methods, and that in vivo effects are the result of several factors, 
                                                          
2
 Although some participants of the workshop felt that the concepts of MoA and AOP were interchangeable, in this report, we use 
the definition according to Ankley et al.: the AOP includes exposure and adverse effects and encompasses the MoA, which is the 
Molecular Initiating Event through cellular and histological changes associated with the adverse effect.  
3
 In order to emphasize key ideas, we have slightly rearranged the order of the original presentations in this publication. The 
Workshop Agenda and presentations are available on the Human Toxicology Project Consortium website: 
HumanToxicologyProject.org 
4
  All participants were invited.  Individuals attending presented their personal views and were not necessarily representing the views 
or policies of their respective institutions. 
5
 As described in the OECD (2013) definition of AOP. 
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while in vitro tests generally measure one or only a very few of these factors.   Currently, for several in vitro and in 
silico models, 25% of chemicals at one end are correctly predicted toxic, 25% at the other end correctly predicted 
non-toxic; the trouble lies in correctly predicting the 50% in the middle.  Improving the certainty of these predictions 
will require transparency of the mechanism involved in generating the observed outcome, determining probability that 
the mechanism occurs and is causally linked to the outcome, employing weight-of-evidence from different lines of 
support, and the ability to do hypothesis testing with rapid and inexpensive methods.   
AOPs provide the mechanistic basis for justifying alternative approaches.  They are a framework comprised 
of the events at the different levels of biological organization and other key dimensions (e.g., gender, life stage etc.) 
and their causal relationships.  The features of an AOP are: a single molecular initiating event (MIE), a single 
outcome, and any number of intervening ‘key events.’ Key events are intermediate events that are toxicologically 
related to the adverse outcome; they must be quantifiable and measurable (ideally using rapid in vitro or in silico 
methods) and are used to test AOP hypotheses.  The rationale for focusing on a single MIE and a single outcome is 
to have a concrete starting point; once several AOPs are described, they can be connected and grouped.  Each AOP 
must be well-documented, plausible, and testable.  Though an AOP can be minimally described with the beginning 
MIE and ending outcome, confidence in its predictions improves as its details are elaborated, in particular as its key 
events are identified and described.   
AOP development can begin anywhere in the sequence of events, but the actual starting point usually 
depends on who is initiating the description.  For example, a chemist will likely start at the molecular initiating event, a 
regulator will likely start at the adverse outcome, and a systems biologist will likely start somewhere in the middle and 
walk to both ends.  The best way forward is for all to communicate.   
Demonstrating the adequacy of the AOP involves assessing the experimental support for key events, the 
weight-of-evidence according to Bradford Hill criteria, and how well it scales from in vitro to in vivo outcomes.  
Difficulties in developing and using AOPs are introduced by several factors:  separating the mechanism from 
symptoms, which often depends on the perspective of the expert (again, a chemist is likely to have different opinions 
than a pathologist); separating events that control potency from events that confirm that the AOP is being followed; 
achieving consensus on key events; and reaching agreement on an appropriate test method for the key event. 
There are a number of uses for AOPs in addition to providing the mechanistic basis for justifying alternative 
approaches to meeting legislative testing mandates: AOPs are a means of recording and formalizing toxicity pathway 
information; they assist in directing targeted testing; they can be used to develop a better chemical category for read-
across (for comparison of data from one chemical to a related chemical); and they can be used for developing 
integrated approaches to testing and assessment (IATA) to prioritize testing and for developing integrated testing 
strategies (ITS) to replace in vivo testing (the distinction being that, in IATA, if a chemical does not pass the first tier 
of testing, it doesn’t proceed to a second tier while in contrast, in an ITS, testing is performed as necessary to gather 
all the information needed for a given purpose).  The level of knowledge required for any AOP will vary according to 
its use.  For example, qualitative relationships in a pathway are adequate for hypothesis generation, but not for risk 
assessment.  The key at this stage is to move beyond the concept and theory of AOP creation into the generation of 
data within the laboratory in order to form robust, testable, and ultimately functional AOPs tailored to the use for 
which they will be employed. 
 
3.2 Mapping the Human Toxome for new regulatory tools and updates and perspectives from the Center for 
Alternatives to Animal Testing (CAAT) PoT workshop – Andre Kleensang 
Under the current toxicity testing paradigm, approximately $3 billion in toxicology testing is spent to regulate $10 
trillion in trade each year (Bottini and Hartung, 2009).  This approach is extremely costly in terms of dollars and 
animals, and despite the costs, is inadequate for the numbers of chemicals (let alone mixtures) that require testing 
under various regulatory programs around the world, requires extrapolation from extremely high doses to the low 
dose situations likely encountered by individuals, is difficult to scale to new hazards and technologies, and carries 
results that are potentially compromised by inter-individual and -species differences.  In addition, the traditional 
strategy has low predictive capacity, and is overly precautionary: for example, if aspirin had been introduced under 
current testing regulations, it probably would not have made it to market, having exhibited skin, eye, and respiratory 
irritation, high overdose risk, and embryonic malformations in a number of animal models.  And yet, aspirin is one of 
the safest drugs for humans (Hartung, 2009). 
The NRC’s 2007 report entitled Toxicity Testing in the 21
st
 Century presented an opportunity for radical 
change, emphasizing a mechanistic understanding of disease and toxicity derived from tools and approaches like 
genomics, proteomics, metabolomics, high-throughput screening (HTS), computational modeling and systems 
biology.  These tools allow probabilistic instead of deterministic risk assessment (Hartung et al., 2013).  We currently 
measure the adverse outcomes (phenotypes), but what we would rather measure are the causal events.   
One approach to identifying these events is through the concept of Pathways of Toxicity (PoT).  The basic 
assumption here is that PoTs are not novel pathways, but ordinary biological pathways that are perturbed by 
chemical exposure.  The PoT starts at the molecular level events and ends at the cellular responses to them - which 
corresponds to the molecular initiating event (MIE) and cellular responses of an AOP. A PoT has been recently 
defined as a molecular definition of the cellular processes shown to mediate adverse outcomes of toxicants. It is 
assumed that there is a finite number of PoT and we already have a great deal of knowledge to build upon. Further 
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elucidation of the universe of PoT involves the use of all types of ‘omics information; there are many lines of evidence 
and potential contributors to this process that need to be coordinated (for further details, see Kleensang et al., 2013). 
The requirements imposed by regulatory programs like REACH call for greater use of Integrated Testing 
Strategies (ITS) which integrate different sources of information, including prior evidence, and allows for the 
establishment of interim decision points and the collection of sufficient evidence for a particular purpose (European 
Commission, 2005).  Successful application of ITS requires to make more use of advanced statistical approaches 
and probabilistic prediction models for interpretation of evidence and decision on potential hazards. However, 
regulatory acceptance of advanced mathematical models is traditionally very difficult to obtain (e.g. Hoffmann et al., 
2012).  
Another regulatory useful tool could become evidence-based toxicology (EBT, which is modeled on 
Evidence Based Medicine). EBT informs a validation process that can be used to assess the PoT approach and any 
associated ITS (Stephens et al., 2013). A proposal for a ‘mechanistic validation’ using EBT principle has recently 
been put forward (Hartung et al., 2013). EBT principles are transparency, consistency, and objectivity that help to limit 
the bias in review of relevant studies while still leaving room for professional judgment in how to inform 
policy/decisions making.   
Using these approaches (PoT, ITS and EBT), CAAT has formed a multi-stakeholder team to map the human 
toxome.  The input into this process includes in vitro characterization of model systems, combined with high content –
‘omics data and statistical modeling and visualization programs.  In October 2012, CAAT hosted a workshop on tools 
for PoT development – including a PoT database (because on one hand existing toxicity databases are not pathway 
oriented, and on the other hand existing pathway databases are not toxicity oriented). 
 
3.3 Hamner Nuclear Receptor AOP Projects: PPARα and ER – Mel Andersen 
The 2007 NRC report, Toxicity Testing in the 21
st
 Century: A Vision and A Strategy, proposed use of in vitro tests 
querying perturbations of toxicity pathways for the purposes of quantitative health risk assessment from in vitro assay 
results (Krewski et al., 2010).  These toxicity pathways are normal signaling pathways, the perturbations of which can 
lead to toxicity.  In the larger AOP context, toxicity pathways are sub-components linking molecular initiating events 
through integrated cellular responses on to adverse apical responses.   
While AOPs provide useful narratives for showing the connection of individual biological processes, they 
lack a strong quantitative basis for risk assessment.  Designed-for-purpose toxicity pathway assays promise to 
provide key data for complete risk assessments based on in vitro results.  The Hamner Institutes in Research 
Triangle Park, NC has embarked on a series of toxicity pathway case studies to develop integrated data sets on 
toxicity pathways (www.thehamner.org/tt21c), pathway assay read-outs, and both in vitro-in vivo extrapolation and 
computational systems biology pathway modeling for dose response extrapolation (Bhattacharya et al., 2011).   
One of our case studies with the p53-mdm2 DNA-damage repair pathways contains all the individual 
components for moving from assay output to risk assessment (Andersen et al., 2011; Bhattacharya et al., 2011).  In 
this p53 work micronuclei formation in vitro serves as at marker of adversity in the pathway assay with various human 
cell-type (Sun et al., 2013).  Overall the opportunity to accelerate the TT21C with case studies was emphasized in a 
human toxicology project workshop (Stephens et al., 2012).  Two other Hamner projects focus on nuclear receptor 
pathways for estrogen signaling in uterine cells and for PPARα signaling in liver.  For both of these examples, the 
measure of adversity is regulation of cell proliferation and affects of proliferation on neoplasia. The PPAR pathway 
project also serves as a prototype for the larger group of liver nuclear receptors that cause enzyme induction, tissue 
hyperplasia and liver tumor promotion. This sequence of biological events is characteristic of the AOP for liver 
enzyme inducers. 
Pathway Prototypes:  With the nuclear receptor case studies, Hamner is furthest along our PPARα project.  
The approach has focused on examining responses in primary hepatocytes from rat and from humans and in 
comparing rat in vitro results with responses of rat liver after treatment with a PPAR agonist.  Our test compound was 
the PPARα selective agonist, GW7647.  We have collected a dense data stream – transcriptomic signatures across 
dose and duration of exposure, CHIP on Chip analysis to evaluate DNA binding sites of PPARα at different times, 
and metabonomic analysis of the cellular ‘secretome’ associated with GW7647 treatment of human hepatocytes to 
assess correspondence between gene regulation and metabolic alterations in cells.  Analysis of these rich data sets 
required further elaboration of bioinformatic tools for describing relationships among data sets and for visualization of 
the interrelationships among data sets – including gene transcription, DNA binding, metabolite production and 
transcription factor recruitment (McMullen et al., 2014).  More recent efforts have required linking metabolic reaction 
pathway networks to metabolites and altered gene expression using tools such as the reactome (www.reactome.org) 
and other data bases.  The final goal is creating a quantitative dose response model for the signaling network that 
drives proliferation in hepatocytes using computational systems biology pathway models – CSBPM (Zhang and 
Andersen, 2007; Zhang et al., 2010).  The development of in vitro toxicity pathway assays for specific modes-of-
action will also serve to accelerate work on other toxicity pathways.  This iterative process, learning from one case 
study to accelerate work on subsequent pathways,  is most clear as we look from PPARα to other hepatic nuclear 
receptors with hepatic toxicity of one form or another, including CAR, PXR, and AhR (although the latter is not 
formally a liver nuclear receptor family protein).    
Another aspect of our efforts is creating a measure of confidence that the responses examined with in vitro 
ALTEX Online first  





assays correspond, at least qualitatively, to responses in intact organisms.  This step in essence is a small check on 
the correctness of linkages from toxicity pathways, to mode-of-action, and onto a liver AOP.  In our work we examine 
in vivo hepatic responses after GW7647 with in vitro measures both in the presence and absence of mitogenic 
signals (glucocorticoids) augmenting GW7647-induced responses in hepatocytes.  It bears emphasis, however, that 
the goal of developing these in vitro toxicity pathway assays is NOT to predict quantitatively high dose apical 
responses in rats or humans.  These assays are intended to provide a self-contained dose-response adequate for 
assessing regions of safety for human exposures rather than providing an apical response on which to derive a 
conventional risk assessment.  Several previous contributions have addressed this important distinction between a 
conventional risk assessment and regions of safety (Andersen and Krewski, 2010; Thomas et al., 2013). 
 Cellular response studies of toxicity pathways became the central element of our research program with 
case studies, requiring evaluation of the dose response for specific molecular and cell level responses and the 
mapping and modeling of pathways and pathway perturbations.  The process seeks to organize data sets in order to 
recapitulate the signaling network components and the response dynamics (Andersen et al., 2013). We are pursuing 
a similar approach in our endocrine disruption toxicity pathway program, called “Tier one and done” – a title 
emphasizing that in vitro tests should be complete for future risk/safety assessment activities for most chemicals in 
commerce.  For estrogenic signaling we are examining responses in human uterine epithelial cells (the Ishikawa 
adenocarcinoma cell line) and using linkages to rat uterotrophic assays to insure relevance of the in vitro model 
(Kwekel et al., 2005).  We examine the time and dose response of the Ishikawa cells, DNA binding of forms of the 
estrogen receptor and bioinformatic processing to assess the signaling network.  Hamner is fortunate that the work 
has found support through a partnership with of funding groups, including the ACC-LRI, Dow Chemical, ExxonMobil 
Foundation, Dow Corning Corporation, Agilent, Illumina, the Human Toxicology Project and others.  We emphasize 
that the development of AOP narratives will be useful as long as they provide a basis for identifying specific assays 
that can provide key in vitro inputs sufficient for the purposes of risk assessment.  A danger is that the toxicology/risk 
assessment community will see no value in mechanistic work until every step involved in apical AOPs have been 
established in intact organisms. 
 
3.4 SEURAT AOP project: Oct 2012 workshop update – Brigitte Landesmann 
SEURAT-1 (Safety Evaluation Ultimately Replacing Animal testing), the largest EU research initiative on alternative 
methods, is a public-private partnership between the European Commission and the European Cosmetics 
Association (COLIPA, now Cosmetics Europe).   This research cluster consists of six individual projects (Scr&Tox, 
HeMiBio, DETECTIVE, COSMOS, NOTOX, ToxBank and a coordinating action (COACH).  The vision of SEURAT-1 
is to fundamentally change the way we assess the safety of chemicals, by superseding traditional animal experiments 
with a predictive toxicology that is based on a comprehensive understanding of how chemicals can cause adverse 
effects in humans.  The strategy is to adopt a toxicological mode-of-action (MoA) framework to describe how a 
substance may adversely affect human health, and to use this knowledge to develop complementary theoretical, 
computational and experimental (in vitro) models that predict quantitative points of departure needed for safety 
assessment.  Proof of SEURAT-1 concepts is done at three levels: on the first or theoretical level, selected MoAs are 
described to a sufficient extent so that they can be used as blueprints for system design; on the second or systems 
level, integrated systems are designed based on the elaborated MoAs for associating a chemical with a MoA 
category and for quantitative prediction; on the third or application level, the information derived from predictive 
systems is used to support safety assessment processes and decisions.   
The SEURAT-1 workshop on MoAs/AOPs in liver toxicity held in October 2012 was similar in intent to the 
current workshop: to evaluate the processes and tools for describing an AOP or MoA based on elaborated examples, 
and to consider the practical applications of this MoA/AOP knowledge within SEURAT-1 projects.   
Key points resulting from the SEURAT workshop were:  
 There is great need for harmonization and standardization of AOP descriptions, namely a common language 
with an agreed common ontology of toxicological terms and new descriptive terms to represent the 
functional and dynamic relationships between elements of a pathway and between pathways.  
 The complexity of pathways might be better presented by a multi-dimensional description with several 
matrices and using a symbolic language.    
 AOP development should not be considered a one-off activity, but an iterative process with constant 
expansion according to newly generated data. With growing knowledge, the gaps are filled and the AOP 
becomes increasingly more accurate and refined. Ideally this should be achieved through a crowd-sourcing 
process and then be evaluated by the international scientific community (with some kind of controlled access 
and quality control).   
 Computational models and tools are indispensable to support the AOP development process (e.g. for 
literature mining, quantitative assessment, simulation of probable scenarios etc.). 
 The application of AOP knowledge for the design of an integrated test system is different from the 
experimental design suitable for development and elucidation of AOPs. 
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 Rational (knowledge- and not empirically-driven) design of an integrated test system is dependent on having 
a sufficiently (qualitatively and quantitatively) described and understood AOP and a clearly defined purpose 
beforehand. Experimental design should not aim at mimicking whole humans in an in vitro model.  
Further challenges identified from the SEURAT workshop were: 
 Linearity: according to the AOP concept the sequence of events appears linear to simplify and better 
visualize the described events. Obviously the complexity of biological processes and the dynamic 
relationships between the various actors cannot be fully captured by linear processes and the mechanisms 
behind the key events on each level of observation cannot be fully described in a linear fashion. The amount 
of detail and apparent linearity depends on existing knowledge and on the purpose for which the AOP is 
intended. 
 Kinetics: kinetic information is critical and needs to be considered in the design of a test system, but there 
are substantial practical difficulties for implementation 
 Animal data: how relevant is animal data for human health risk assessment? 
 Drugs:  data rich but are they also good references for other kinds of chemicals?  
 
4 AOP development and use in decision-making 
MoAs and/or AOPs are already in use in several regulatory contexts; for assisting in decision-making regarding 
human relevance of animal data, to design integrated assessment strategies, and to support interpretation of both in 
vitro and in vivo data.  In general, the confidence and completeness of an AOP will determine its utility: less complete 
AOPs can be useful for chemical categorization and prioritization of chemicals for further testing while AOPs with high 
confidence and quantitative understanding of the links between events are necessary if they are to be used to inform 
risk assessment.     
 
4.1 The Use of MoAs/AOPs in EPA’s Office of Chemical Safety and Pollution Prevention -  Jennifer Seed 
The Mode-of-Action (MoA) framework was originally developed by the human health risk assessment community to 
provide a weight of evidence approach for determining relevance of animal findings to humans, first for cancer and 
then for other endpoints.  For the EPA’s regulatory purposes, there is little difference in the concepts of MoA and 
AOP; MOA was developed by the human health community while AOP was developed by the ecological 
community.  The MoA describes the key, rate limiting, and quantifiable key events that lead to adverse outcomes.  
As other presenters have noted, description of key events is often the most difficult part in developing a MoA.  The 
EPA has long recommended using the Bradford Hill criteria to guide evaluation of a proposed MoA in order to 
decide whether there is support for the identified steps in the pathway, pointing out where the holes are, and 
determining what information is still needed.  In terms of human relevance of animal data, the first question is 
whether the weight of evidence is sufficient to establish the MOA in the animal model being used.  If so, are there 
qualitative and/or quantitative differences in key events between the animal model and humans?  
The EPA’s Office of Chemical Safety and Pollution Prevention uses both the MoA framework (for cancer 
and non-cancer) and the OECD’s AOP guidance.  The use depends on the regulatory question being asked, and 
the context of the regulatory decision determines what level of uncertainty is acceptable.  EPA has a long history of 
pathway use to prioritize information needs and also to gain some preliminary hazard assessment in areas with 
limited data (e.g. toxics, pesticide inert ingredients). MoAs are generally used as part of a weight-of-evidence and 
rarely is there a complete MoA or AOP – rather the framework is one method in the chemical evaluation toolbox.  
Many different components go into a screening-level assessment, including several QSAR and SAR models 
for specific endpoints and for exposure (e.g. phys-chem and fate via EPISuite, Aquatic Toxicity via ECOSAR, 
Carcinogenicity via OncoLogic, Non-Cancer Effects via Analog SAR, Exposure Potentials via E-FAST and 
ChemSTEER).  MoAs have been used for several purposes within the context of screening-level assessments: 
 Development of predictive tools – e.g. the Oncologic expert system to determine carcinogenic potential 
 Chemical prioritization using existing information and partial MoAs, e.g. disinfection byproducts for 
potential carcinogenicity and the estrogen receptor expert system for antimicrobial pesticide and pesticide 
inert ingredients 
 Use in read-across for industrial chemicals 
 Development of targeted testing strategies – e.g. for thyroid and developmental neurotoxicity 
 Use in cumulative risk assessment: common mode-of-action is the basis for the cumulative assessments 
for large chemical categories; MoAs guide the identification and description of exposure scenarios, guide 
the selection of common endpoints, determine toxic potencies and points of departure (PODs) for 
chemicals of interest, etc. 
In summary, EPA has been utilizing the MoA approach for a number of years and it is being applied in a 
number of ways.  Though there has been much progress in the development and use of MoAs, there is still a long 
way to go.  The current library of MOAs is growing to cover a larger range of endpoints.  While historically EPA has 
had to work back from adverse outcomes, better tools are now available for working forward from MIEs; the 
challenge continues to be linking the MIEs to the adverse outcomes. 
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4.2 Adverse Outcome Pathways: application in consumer (and environmental) safety risk assessments --   
Carl Westmoreland 
The key question at Unilever is whether a new ingredient can be used safely at the percent concentration 
necessary in a product and considering the intended use.  Risk assessments are driven by how much exposure is 
likely.  The route and amount of exposure determines the endpoints of concern, and preexisting information is used 
wherever possible to determine what additional information is needed. The goal is to avoid human adverse 
outcomes altogether.  
In that light, in an example of the use of an AOP to address skin sensitization, the first task is to identify 
pathways to skin sensitization in humans, then to design methods to test key events in the pathway, and finally to 
ask whether a chemical’s response indicates an adverse reaction under the expected exposure scenario.  
For skin sensitization, the pathway has been fairly well characterized and includes several key events for 
which there are in vitro or in vivo assays including: skin penetration, the existence or metabolic creation of an 
electrophilic substance, covalent binding to proteins, activation of keratinocytes and dendritic cells in the epidermis, 
and activation of T cells in the lymph node. The approach is to generate data relevant to the exposure context in 
vitro, then use the data as inputs into two linked mathematical models that predict the magnitude of a human 
immune response.   
Unilever is in partnership with other institutions to investigate several other pathways, including 
mitochondrial toxicity and DNA damage.  Applying 21
st
 century science to an AOP approach to DNA damage 
includes obtaining dose-response, high content ‘omics information and the application of computational models 
based on the relevant pathway circuitry.  Measuring the in vitro concentrations is very important – actual in vitro 
concentrations must be extrapolated to in vivo target site concentration, and finally via PBPK modeling to exposure 
concentrations.   Unilever does not yet perform probabilistic modeling, but is working toward that goal. 
Case studies not only provide a needed proof-of-principle, but are beneficial in that they require people 
from multiple disciplines to work together and emphasize the importance of including experts in several different 
disciplines (modelers, chemists, biologists, etc.).  They also provide clarity to the problem and help identify the 
information that is key for decision-making.   Interestingly, the AOP concept has allowed for the first time the 
human health and eco-toxicologists to speak the same language and has facilitated interaction between the two 
groups.   
 
4.3 Adverse Outcome Pathway Development: Sustained Activation of the Aryl Hydrocarbon Receptor -   Katy 
O. Goyak 
The American Chemistry Council’s Computational Profiling and Risk Assessment Work Group is working to evaluate 
alternative approaches to hazard and risk assessment, including AOPs.  The Aryl hydrocarbon Receptor (AhR) 
adverse outcome pathway (AOP) project is being developed in coordination with the Business and Industry Advisory 
Committee to the OECD (BIAC) and Environment Canada and began with a TERA workshop in 2010.
6
  The goal of 
this project is to bridge the gap between in vitro observations and risk assessment and it provides an opportunity for 
collaboration between regulatory, academic and industry scientists to further enhance methods for risk assessment. 
The MIE for the AhR AOP is sustained activation of the aryl-hydrocarbon receptor with key cellular events 
being decreased apoptosis and increased proliferation, and key tissue events being altered foci in hepatocytes 
followed by hepatic tumors and biliary cholangiofibrosis or biliary tumors as adverse outcomes.   Information from rats 
and humans indicates that there is some evidence for conserved cellular responses and less evidence for conserved 
tissue responses, such as altered foci or hepatic tumors. Comparison of in vitro primary hepatocyte responses to 
TCDD (an AhR agonist) between rats and humans as measured by CYP1A1 (100X) and CYP1A2 (10X) induction 
indicates that human cells are less sensitive than rat hepatocytes to AhR activation.   
This MIE is associated with different adverse outcomes in different species: liver tumors in rodents, embryo 
lethality in avian species, chloracne in humans, and early life stage deformities and lethality in fish.  The different 
AOPs will be dealt with in stages, with liver tumorigenesis and embryo lethality being first, and chloracne and early 
life stage deformities in a second phase. Clear guidance regarding the development and use of AOPs would be 
beneficial to this process, as well as coordination between groups working on AOPs (e.g. the molecular screening 
expert and the QSAR management groups at the OECD) to better understand what factors are considered for 
evaluation and acceptance of AOPs.  
 
4.4 Cutaneous metabolism - Daniel Duché 
Although not working on the liver, L’Oreal is studying another important aspect of metabolism, the metabolic function 
of the skin. The skin is the largest organ of the body (15% body weight vs. 2% for the liver), yet much less is known 
about its metabolic capacity than is known about the liver.  L’Oreal has done much work developing and using 
reconstructed human skin models from different sources of epithelial cells.  Analyses of these tissues include gene 
and protein expression and enzymatic activity to characterize expression and activity of Phase 1 and Phase 2 
metabolizing enzymes.   
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 TERA. Workshop on Dose-Response Approaches for Nuclear Receptor-Mediated Modes of Action. September 27-29, 2010. More 
information available at http://www.tera.org/peer/nuclearreceptor/. 
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The reconstructed skin models such as those developed by L’Oreal (e.g., EpiSkin) have largely the same 
metabolic enzyme activity profiles as normal human skin, but there are some differences: the reconstructed skin 
models have relatively low basal expression and activity of the CYP450s involved in drug metabolism.  It is clear that 
the metabolic capacity of skin is primarily to detoxify (rather than activate) chemicals, and in three different case 
studies of hapten-causing skin sensitization (p-Phenylenediamine, CIN-OH, 1-chloro-2,4-dinitrobenzene), toxicity 
occurs when the detoxification system becomes saturated.  
In summary, the reconstructed skin models function similarly enough to normal human skin to be useful in 
predicting human metabolism and toxicity.  The metabolic capacity of human skin is primarily to detoxify chemicals, 
and toxicity occurs when the skin’s detoxifying capacity is overwhelmed. 
 
 
5 Discussion on best practices in AOP development 
 
Led by Carl Westmoreland, the discussion following the first sessions focused on ‘best practices’ for AOP 
development.  First, consensus was reached on the basic elements needed for pathway development, including an 
established MIE and an AO that are linked by any number of intermediate events.  One issue on which consensus 
was not reached was the limitations that this structure might impose on AOPs; i.e., must every pathway end with an 
AO at the individual or population level and must every pathway be strictly linear without branching?  Biologically a 
chemical can result in more than one AO from a single MIE or may have multiple MIEs; however, in practice, an AOP 
built using specific chemicals as case examples is likely to be initially built from one MIE to a single AO, and it is 
envisioned that multiple, linear AOPs would likely be built rather than a complex, branched AOP.  On the other hand, 
a more holistic view of the branch points would likely eventually be created.  An additional consideration might be to 
group pathways with similar anchors together.  Regardless of the strategy for development, an initial goal is to 
develop a few specific examples in such a way as to make the process generalizable (to other chemicals, to other 
tissues) and the resulting pathways testable. 
Comparison was made between AOP development and similar pathway construction efforts following 
alternate frameworks, such as the biological anchoring of QSARs, MOA Human Relevance Frameworks, and toxicity 
pathway identification.  One issue raised was whether every conceivable MIE needs a pathway, or, alternatively, 
does every pathway need an MIE?  Thorough description of every conceivable pathway may not be necessary to 
capture the full spectrum of biological consequences of chemical exposure. 
One distinguishing feature of AOPs from other pathway frameworks may be that the intended use of the 
AOP can result in different levels of required detail. As such, use should be considered a necessary and fundamental 
element in the development of an AOP.  Since the pathways are designed for a purpose, the design will be different if 
you are accurately predicting toxic effects or predicting regions of safety (i.e., non-toxic exposure levels).  In risk 
assessment for complex endpoints, it is critical to take homeostasis/recovery/repair (feedback loops) into account in 
the pathway.  It is also critical to add quantitative information to the relationships between events – for example, with 
mitochondrial toxicity/ATP production, the threshold is high but the dose-response is steep.  Furthermore, it may be 
necessary (in human health risk assessment) to take inter-individual variability into account. There may also be 
different classes of pathways, such as  receptor-mediated (recognition) and reactivity (protein or DNA damage) 
pathways.  Nonetheless, are these classes qualitatively different? Both quickly cause changes in gene expression, so 
the pathways may actually be similar in dynamics and structure. Overall, the importance of the hypothesis or 
hypotheses should be emphasized; it is important to be objective and not be too attached to a particular hypothesis 
that might interfere with the recognition of other factors and relationships. 
Depending on the intended use, the various elements of an AOP might need different levels of scrutiny.  For 
example, a thorough description of the MIE is necessary for QSAR modeling, while a more general understanding of 
the intermediate events without a detailed MIE might be useful for designing integrated testing strategies.  In some 
cases, identifying and measuring intermediate events in a pathway may be more useful, allowing the capture of 
multiple MIEs and broader coverage of potential routes to the AO.   
A main objective of an AOP is, in part, to assist in test design, so an AOP should provide a clear 
organizational framework (e.g., in an integrated testing strategy) to aid the effective and accurate prediction of 
toxicity, and perhaps more critically, regions of safety.  As part of this focus on chemical testing strategy, the OECD 
has developed guidance, in part, based on suggestions from the PoT and JRC workshops, to provide an initial 
evaluation and assessment of AOPs.  Participants were generally in agreement that the suggested OECD principles 
of data and causal relationship evaluation are appropriate.  Furthermore, there was consensus that if an AOP relies 
entirely on comparisons with animal results (where concordance is not all that good), the system is limited. Thus, 
there is a desire to incorporate measures of human relevance of the AOP where possible. 
Participants agreed that future activities in AOP development should include further definition and 
identification of intermediate events, and that establishing a library of “key” events would be useful.  Whether or not 
an event is “key” may, of course, depend on the pathway and the data to support causality between events.  In 
addition to a library of key events, a centralized reference or guidance and published examples of pathways are 
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  This could be achieved through crowd-sourcing or gaming-specific problems and data challenges; these 




6 Pathways relating to liver toxicity 
 
Because liver toxicity is prevalent in acute, chronic, and subchronic chemical exposure - whether due to repeated 
exposure to environmental chemicals, or to drugs (where liver toxicity is a leading cause of removal from the market) 
– it is an especially appropriate subject for pathway case studies.  Drug-induced liver injury (DILI) is rare, making it 
hard to detect in preclinical testing and clinical trials, but it can be life-threatening (requiring liver transplantation) or 
fatal for an affected individual.  In addition, any indication of liver toxicity during drug development, whether in animal 
studies or in vitro, may result in abandonment of the drug, and promising therapeutics are likely to be inappropriately 
discarded.    
DILI can also be highly dependent on the patient’s own genetic makeup and physiological condition. While 
there are described diagnostic markers for DILI, these are not specific, and more importantly, are not predictive of 
future occurrence.  Understanding liver toxicity therefore requires an in-depth understanding of normal liver function 
as well as the pathway perturbations.  Pathway-based approaches to liver toxicity and DILI are important for 
identifying predictive biomarkers.   
 
6.1 Drug-induced liver injury: mechanisms and types --‐   Mathieu Vinken 
While drug induced liver injury (DILI) is infrequent (1 in 10,000 to 100,000 patients per year), it is responsible for 
50% of the cases of liver failure, and most of these are due to reactions to acetaminophen.  The types of drugs 
most commonly associated with liver toxicity are antibiotics, central nervous system drugs, and non-steroidal anti-
inflammatory drugs.  Animal toxicity studies pick up about 50 – 70% of the drugs that will cause liver toxicity; in vitro 
studies will detect about 50 – 60%.   To detect liver injury in clinical trials, the trial size would need to be on the 
order of 30,000 patients, rather than the standard 2,000 – 5,000.   
DILI can be acute or chronic and be of two types: intrinsic (also called A-type; associated with the drug’s 
activity, dose-dependent and has a latency of only hours or days), or idiosyncratic (also called B-type; not dose-
dependent, has a latency of weeks to months).   Idiosyncratic DILI can be further subdivided into two types, 
metabolic and immunologic, based on the origin of the cause.  These types are often not easily distinguished, the 
latency period making identification of the cause difficult.  Regardless of the type of DILI, there is thought to be a 3 -
step process, beginning with an initial cellular injury (by a parent drug and/or its metabolites) resulting in direct cell 
stress, induction of an immune response or direct mitochondrial inhibition; followed by mitochondrial permeability; 
and resulting in cell death (apoptosis or necrosis) (Russmann et al., 2009)).   
Acute DILI can be subdivided into cytotoxic (resulting in cellular injury) or choleostatic (resulting in a block 
in the flow of bile).  Acute DILI often manifests as hepatic necrosis, hepatocellular steatosis and/or degeneration or 
acute cholestasis, whereas chronic liver injury can manifest in a number of conditions including hepatitis, steatosis, 
fibrosis, phospholipidosis and neoplastic lesions.   
Following the 3-step model of DILI, the first step, as an example, might include direct cell stress as the 
cause of the initial cellular injury.  Direct cell stress may cause necrosis and/or degeneration  of the cell.  It can also 
cause steatosis (a build-up of fatty acids in hepatocytes).  Steatosis occurs via several mechanisms:  impaired 
beta-oxidation (e.g. amiodarone), increased de novo synthesis of fatty acids (e.g. valproic acid), damage to 
mitochondrial DNA (e.g. zidovudine), and altered secretion of very low density lipoprotein (e.g. tetracycline).  A 
lesion that presents similarly to steatosis histologically is phospholipidosis.  Phospholipidosis is a reversible 
accumulation of lipids caused by drugs with a cationic amphiphilic structure.  Phospholipidosis can be caused by 
increased phospholipid synthesis and/or decreased phospholipase activity.  The clinical relevance of 
phospholipidosis is not clear; it could result in liver injury or be an adaptive response to liver injury.  Cholestasis can 
also result from direct cell stress via several mechanisms, including: inhibition of Na+/K+ ATPase (e.g. 
chlorpromazine), inhibition of BSEP (e.g. glibenclamide), and agonism of MRP/P-glycoprotein (e.g. estradiol 17beta-
glucuronide) but can also occur indirectly via swelling of hepatocytes and blockage of bile canaliculi. 
Another possible cause of initial cellular injury in the 3-step model is induction of a specific immune 
response against the liver, likely involving induction of both innate and adaptive immunity.  Involvement of the 
immune response results in production of cytokines and activation of B and T cells.  Inflammation generally results, 
although cytokines themselves can be pro- or anti-inflammatory. To cite one example, idiosyncratic or B-type DILI, 
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An AOP Knowledge Base (AOP KB) is currently being implemented as OECD project to facilitate the contribution to and evaluation 
of AOP information collected by a wide range of experts. Currently a beta version is available only for OECD AOP development 
teams, but from January 2014 on it will be publicly accessible. 
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 For example, “Fold-it” (http://fold.it) invites players to design or predict protein structures (“Predicting protein structures with a 
multiplayer online game.” Seth Cooper, Firas Khatib, Adrien Treuille, et al. Nature 466, 756-760 [2010]). “Ete RNA” 
(http://eterna.cmu.edu/web/) players design RNA molecules and compete for the chance to have their molecule synthesized (“RNA 
design rules from a massive open laboratory.” Jeehyung Lee, Wipapat Kladwang, Minjae Lee, et al. PNAS Early Edition, 
www.pnas.org/cgi/doi/10.1073/pnas.1313039111. 
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involves the adaptive immune system and symptoms take 1 – 4 weeks to develop. One proposed mechanism for 
this is the hapten induction hypothesis, which theorizes that drugs (e.g. halothane, diclofenac or dihydralazine) 
covalently interact with proteins to form haptens.  These haptens are then processed by dendritic cells and 
fragments are presented via major histocompatibility complex (MHC) proteins to T cells that then activate the 
inducible immune response (activated T cells and antibody-producing B cells).  An alternative mechanism 
hypothesis (the pharmacological interaction (p-‐i) concept) is that some drugs (e.g. lamotrigine, carbamazepine, or 
sulfamethoxazole) bind directly to MHC molecules and mimic T-cell antigens, thereby activating T cells directly.  
Following the initial cell injury (either direct cell death, induction of an immune response, or direct 
mitochondrial inhibition), the second step in the three-step DILI model is induction of mitochondrial dysfunction, 
such as by disruption of the permeability transition pore (PTP).  The PTP regulates the uptake of water and release 
of Cytochrome C.  The extent of PTP opening determines the degree of ATP depletion, which in turn determines 
the mode of the third and final step in the three-step DILI model, cell death.  A greater depletion of ATP leads to 
necrosis, a lesser depletion leads to apoptosis. 
Whatever the cause of DILI, be it Type-A intrinsic or Type-B idiosyncratic, repeated, chronic insults that 
cause cycles of cell death and re-growth will result in liver fibrosis.  Liver fibrosis can be a reversible process and is 
induced by a range of drugs including oral contraceptives and exposure to methotrexate. Key events in fibrosis 
include: activation of stellate cells to myofibroblast-like cells, loss of vitamin A in stellate cells, deposition of 
extracellular matrix proteins, Kupffer cell activation and loss of fenestrae in sinusoidal endothelial cells. 
 
6.2 Drug induced liver injury (DILI) – John Senior 
The FDA is charged by Congress to determine whether drugs for the public use have (1) effectiveness, and (2) 
safety.  It is not really a risk/benefit ratio - but more an assessment of the difference between risk and net benefit.  
The liver serves as the body’s chemical engineering and control center, regulating the metabolism of internal 
compounds and also coping with compounds coming in from the environment, such as drugs.  The liver has a 
remarkable capacity to adapt and regenerate, which can confound predictive models.  
 Approved drugs are by far the most common cause of acute liver failure in the United States.    Drugs are 
not intended to cause harm; however, several widely used drugs cause acute liver failure and liver injury and have 
required regulatory action.  While some drugs are more likely to cause liver injury than others, it is also true that 
some patients are more susceptible to the same drug and doses than others.  
 Acetaminophen is so widely the focus of DILI research because of its very successful marketing 
in the U.S. since 1986, when it was positioned as a “safe” aspirin alternative after the use of aspirin in children with 
“flu” symptoms was associated with onset of Reye’s Syndrome.”  Since many people think of it as safer - and 
assume that if a little is good, a lot would be better - there is a tendency to take too much, leading to toxicity. 
 In order to predict and prevent the occurrence of DILI, we need to know both severity and causality of 
hepatotoxicity.  Severity measures can be misleading. Most people tolerate exposure well; as severity goes up, the 
number of affected individuals goes down and very few experience severe reactions or death.   In addition, due to 
the number of factors involved, causality is very difficult to establish.   
 The study of DILI began following the approval, in 1997, of two drugs, troglitazone (Rezulin: approved 29 
Jan 1997, Parke-Davis, a new class of anti-diabetic drugs) and bromfenac, (Duract: approved 15 July 1997, Wyeth-
Ayerst, a short-term analgesic).  In both cases, patients almost immediately began showing severe, fatal cases of 
centrilobular hepatic necrosis.  Duract was removed from market in June 1998; Rezulin took longer, it was removed 
in March 2000.   
 Identifying a causal relationship between drugs and DILI is difficult and requires a lot of work.  “Hy’s Law” 
established a relationship between biomarkers and the likelihood of DILI and includes the following findings: (1) 
alanine Transaminase or aspartate transaminase greater than 3 times the upper limit of normal, and (2) total 
bilirubin of greater than 2 times the upper limit of normal and (3) not caused by pre-existing disease.  These 
findings, combined with a history of drug administration, would indicate that a drug is a probable cause, but clinical 
adjudication (differential diagnosis) is also required. 
 To help identify DILI cases for evaluation, FDA uses “eDISH” (evaluation of Drug Induced Serious 
Hepatotoxicity), a software program that uses the human ability of pattern recognition combined with the 
computer’s ability to sift through data that would take a human being onerous amounts of time. 
 Regarding DILI risk, questions with regulatory impact include: does a drug cause clinically significant DILI 
in the target treatment population?  What is the clinical signature of the injury?  What ranges of dose and exposure 
are associated with increased risk?   We should ask these questions at all phases of a drug’s life cycle. 
 Patient susceptibility factors are a huge determining feature of DILI; there are no idiosyncratic drugs, the 
idiosyncrasy is in the recipient. That’s why modeling doesn’t always give us the answers.  Predictive biomarkers of 
DILI that identify susceptible patients are needed but do not yet exist. 
 
6.3 Predicting Serious DILI Clinical & Scientific Challenges – Mark Avigan 
Given numerous challenges such as variability in the onset and tempo of DILI and in the drug-specific liver profiles of 
patients, we need to improve at quantifying and managing risk. Since only a small percentage of the exposed 
population gets a reaction, what we really need are biomarkers.  This is the challenge:  to identify biomarkers that will 
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allow us to create a model that can be used to predict which drugs will cause DILI, which patients are susceptible, 
and which cases are likely to undergo clinical resolution vs. progression while still at an early stage of mild liver injury.  
Any model will need to account for the fact that the liver is particularly good at repairing itself.  
In terms of predicting idiosyncratic hepatoxicants, single cell cultures and animal studies have been of little 
help: there is only about 50% concordance (which raises another problem: if a drug shows indications of toxicity in 
animals, it will not be pursued, so many possible human therapeutics may be abandoned).  Improvement in prediction 
for some, but not all, types of hepatoxicants may be obtained using in vitro co-culture systems (hepatocytes with 
mesenchymal cells), multi-parametric (cell viability, mitochondrial functions, Nrf-2 activation, GSH adducts, etc.) and 
high-throughput analyses, and screens for effects on hepatocyte efflux transporters.  So far, in vitro drug screening 
for hepatotoxicity has not modeled risk effects of idiosyncratic susceptibility. 
Current biomarkers of DILI have important limitations: they are non-specific and cannot predict recovery 
versus adverse outcome.  Ideally, biomarkers would have the following characteristics: measurable non-invasively; 
low baseline variability in tolerant populations; appear before the onset of severe hepatoxicity; and be accurately 
quantifiable with a dynamic range in susceptible populations.  Pathways of toxicity and injury reveal opportunities for 
biomarker development.   
The feasibility of finding genetic biomarkers is a function of two factors: the amplitude of the effect, and the 
allele frequency within the affected population.   Extreme phenotypes are ways to start looking at the system: for 
example, people with Alpers-Huttenlocher syndrome have a 1 in 3 chance of going into liver failure if given valproic 
acid.  Identifying the predisposing factor to liver failure development in such a population might allow extrapolation to 
other populations.  Many susceptibility markers are MHC-related.  There is also a rising interest in mitochondrial 
toxicity as a predictor. Because of the reliability and specificity of their release, there is increasing interest in 
circulating RNAs as biomarkers. 
From a biosystems perspective, a key point is that to go from mild perturbation all the way to liver failure is 
usually going to require more than one “hit;” it is going to be a combination of multiple hits.  These hits will be in a 
combination of drug-specific and non-specific hepatotoxicity steps in pathways leading to toxicity.  From the point of 
view of modeling, you may therefore need both drug-specific and non-specific biomarkers. 
Some serious challenges to the development of predictive models include the fact that the injury occurs in a 
complex organ system with many interconnected components, metabolism and clearance of the drug must be taken 
into account, there are competing toxicity and cytoprotective pathways activated at the same time, escape from 
homeostasis can lead to a rapid progression (the course of the disease can change suddenly), both innate and 
adaptive immunity can be involved, the “butterfly effect” can occur (slight differences in  initial conditions can result in 
vastly different results) and different critical combinations of susceptibility factors can occur in exposed populations.  
In summary, absolute predictors of DILI are unlikely.  Predictive modeling of serious DILI will likely be a 
composite of biomarker measures that include circulating mRNA/miRNA, serum/urinary metabolites & P-G 
/epigenetic markers, and biomarker measures would reflect early and intermediate steps leading to DILI progression 
or adaptation/recovery. 
 
6.4 Liver Toxicity Pathways Example: Acetaminophen – Hartmut Jaeschke 
Acetaminophen is a classic case study of liver toxicity and has been extensively studied for many years.  
Acetaminophen is a very safe drug at prescribed doses, but can be fatal in overdose, so acetaminophen represents a 
case where using high dose exposure in animal testing is very similar to actual human exposure scenarios.  
Metabolic activation by P450s is a critical first step in acetaminophen’s mechanism of action followed by protein 
binding/adduct formation.  In the liver, roughly 50% of acetaminophen is metabolized by glucuronosyl-transferases 
and excreted in the bile and plasma, another 30% is metabolized by sulfo-transferases and also excreted.  5 – 10% is 
metabolized by CYP450s into the reactive intermediate N-acetyl-p-benzoquinoneimine (NAPQI), which is either 
deactivated by glutathione-s-transferases and excreted, or reacts with proteins to form protein adducts. During a toxic 
response, cell death occurs; however, protein adducts also form in people and animals under normal therapeutic 
conditions.  It is possible that at low doses and low levels of adduct formation, elimination mechanisms (autophagy) 
prevent toxicity-related damage, but at higher doses adducts cannot be removed fast enough.  The question of 
whether toxicity involves a threshold or hitting a specific critical target is currently being addressed by proteomics.  
Although there is inflammation associated with acetaminophen-induced liver toxicity, there is no associated immune 
response (the protein adducts do not behave like haptens), but it is unclear as to why this is.  
Protein adducts themselves are unlikely to cause cell death, so what is the mechanism?  There is evidence 
of mitochondrial dysfunction and endoplasmic reticular (ER) stress in mice.  One hypothesis is that covalent 
attachment of NAPQI to proteins, especially mitochondrial proteins, initiates mitochondrial dysfunction, which leads to 
oxidative stress and release of mitochondrial intermembrane proteins (e.g. endonuclease G), which cause nuclear 
DNA fragmentation. Glutathione protects against the mitochondrial oxidant stress, which can trigger the opening of 
the membrane permeability transition pore leading to collapse of the membrane potential, ATP depletion and 
eventually necrotic cell death.  An adaptation to the mitochondrial stress is removal of damaged organelles by 
autophagy (mitophagy).  Autophagosome containing damaged organelles fuse with lysosomes, degrading the 
damaged organelles and releases the amino acids, etc., back into the cell to be used as energy material.  Cellular 
toxicity occurs when the cells ability to respond to mitochondrial stress is overwhelmed.  So the mechanism would be: 
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protein adduct formation, initial mitochondrial oxidant stress followed by activation of several upstream MAPkinases 
resulting in activation (phosphorylation) of c-jun-N-terminal kinase (JNK).  Phosphorylated JNK translocates to the 
mitochondria causing the amplification of the stress response, which overwhelms the impaired endogenous defense 
mechansims (GSH, autophagy) leading to cell necrosis (Jaeschke et al., 2012a).   
All of the work described so far was done in mice, so what is the relevance for humans?  The mechanism of 
toxicity was investigated in HepaRG cells, which are derived from human liver tumors, and appears to have many of 
the same features of the response in mice, except that there is no JNK activation in HepaRG cells and no protection 
by JNK inhibitors.  However, APAP-induced cell death in primary human hepatocytes is at least in part dependent on 
JNK activation.  The human response in overdose patients involves the formation of protein adducts, GSH depletion, 
mitochondrial dysfunction and damage, nuclear DNA damage and necrosis – so the overall physiology of the 
response is fairly similar between humans and mice.  There is also sterile inflammation in people as well as in mice, 
but whether it amplifies liver injury or is in response to the damage and only responsible for clearing the cellular 
debris is a matter of controversy (Jaeschke et al., 2012b).  
 
6.5 Making safer new drugs without animal testing - Paul Watkins 
Among the kinds of drug-induced adverse events not predicted well by animals are cardiovascular and hepatic 
toxicities, which are the main causes of drug development failure at all stages and for regulatory actions on drugs 
post approval.  Animals can be much more susceptible than humans to certain drug toxicities and therefore raise 
false safety concerns.  For example, even a few tablets of ibuprofen can cause severe liver and kidney damage to a 
dog.  Hence, ibuprofen would never have progressed to human trials had the dog been used in preclinical testing, yet 
ibuprofen is among the safest drugs in clinical use today.  Conversely, there are many examples where drugs shown 
to be entirely safe in preclinical animal studies can end up causing severe adverse drug events in patients.  
The main causes of hepatotoxicity in patients are “off-target” (i.e. not related to the drug’s intended action) 
and “idiosyncratic” (i.e. resulting from individual susceptibilities).  With idiosyncratic toxicity, the vast majority of 
people can take a drug and it will be totally safe, but a small fraction of individuals will respond badly. 
In terms of minimizing animal sacrifice in drug development, the first question is: can we come up with in 
vitro cell systems that would be as good as in vivo animal testing?  Most scientists familiar with the problem would 
probably agree that we can.  The DILIsym
TM
 (drug-induced liver injury simulation) initiative is a public-private 
partnership with Pharma industry partners contributing money, previously unreleased data, and intellectual capital to 
generate a system for use in modeling DILI.  DILIsym
TM
 version 1a includes information for modeling several different 
species, including mouse, rat, dog and human.  The modeling approach taken is “middle out”, starting with the toxic 
event at the organ level and modeling towards specific pathways and biological processes only as far as necessary to 
explain the species differences in toxicity susceptibility.  The model can also take into account inter-individual 
variability.  The goal is for DILIsym
TM
 to be a routine tool to guide first-in-humans dosing and interpretation of DILI 
mechanistic biomarkers by January 2015.  Because DILIsym
TM
 utilizes data obtained largely from in vitro systems, we 
believe DILIsym
TM
 will substantially limit the use of animals in preclinical safety testing.  
The second question is can human in vitro systems and modeling represent an advance over current 
preclinical safety testing and lead to the complete elimination of animals in the safety testing of new drugs?  An 
important effort in this regard is the Drug Induced Liver Injury Network (to continue funding by the National Institutes 
of Health until 2018) which finds and enrolls in a registry the rare patients who have experienced clinically important 
“idiosyncratic” DILI due to any drug.  Biological samples, including DNA, are collected and archived from each 
subject.  To identify genetic risk factors underlying susceptibility to DILI, we have performed a Genome-Wide 
Association Study (GWAS) on the entire cohort of DILI cases hoping to find general susceptibility factors of all cause 
DILI.  We did not find significant associations; however, it may still be the case that there are common risk factors 
associated with specific subgroups of drugs and a variety of studies are underway at the Hamner Institutes to 
“cluster” drugs for GWAS analysis by common effects on adverse outcome pathways in cultured human cells.  An 
interesting finding is that when sufficient cases of DILI due to a single drug is subjected to GWAS, only HLA alleles 
have been identified as risk factors.  The most impressive association to date is with the antibiotic flucloxacillin: if you 
have one specific HLA allele you have up to an 80-fold increased risk of developing liver toxicity due to this drug.  
These observations mean we have to add adaptive immune responses (between adverse outcome pathways and cell 
death) to the models describing at least some mechanisms underlying of idiosyncratic liver toxicity.   
Each of the subjects in the DILIN registry have agreed to be recontacted and offered enrollment in additional 
studies and it has therefore been possible to develop  liver-like cultures using Induced Pluripotent Stem Cells 
(iPSCs).  The goal will be to prepare these cultures from  DILIN subjects and can compare responses to the 
implicated drug with responses in similar culture systems prepared from individuals tolerant to the drug.  The 
objective will be to observe differences between cases and controls in the initiation of adverse outcome pathways that 
should inform early events that are necessary, but may not be sufficient to cause DILI.  Identification of these events 
should lead to improved in vitro systems to assess liver safety of new drugs in man.  
In summary, cellular systems, including iPSC-derived, liver-like culture systems prepared from DILI patients, 
together with in silico modeling approaches have the potential to reduce or eliminate animal testing while improving 
safety prediction during drug development. 
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6.6 Virtual Liver:  Predicting liver injury -   Imran Shah 
From the information on 544 environmental chemicals in EPA’s Integrated Risk Assessment System (IRIS) database, 
human health risk assessments for 20% are based on liver toxicity.  The liver is a complex, dynamic system and not 
simply a bag of enzymes.  How do you assemble the pieces in a meaningful way so that we can predict toxicity?  One 
objective is to come up with screening tools that could begin to point out and connect molecular initiating events 
(MIEs) that lead to adverse downstream effects; however, there are many pathways to any given adverse effect.  So 
perhaps a more fruitful approach is to start with the histopathology and work backwards to the MIE.  
A main objective of the high throughput toxicology approach being taken by the Tox21 projects is the 
identification of reproducible biomarkers; however, this is a very difficult problem in the absence of biological context.  
If we cannot do this in an entirely empirical way, maybe we can approach it through computational modeling.   The 
Virtual Liver approach involves simulating different aspects of the toxicological process, modeling context by including 
exposure, ADME (using QSAR and in vitro assays), and cellular and histological effects to describe AOPs.  
One question to ask in describing an AOP for a given set of effects (e.g., liver cancer) is how many 
chemicals are there that produce this set of effects in two different species, for example in both mice and rats (Shah 
et al., 2011).  To prioritize chemicals for hepatocarcinogenic assessment, we can use the degree of association 
between nuclear receptor activity seen in humans and the extent of cancer progression you see in rodents.  
In terms of modeling, we are currently ‘stuck’ trying to use cellular effects to model hepatocyte necrosis, 
apoptosis, and proliferation.  The Virtual Liver approach begins with simulating internal exposure and from there 
molecular, cellular and in vivo organ-level effects.   Here is a key distinction with all the other approaches you will 
hear about:  we do not assume there is a particular kind of lesion a priori.  Injury is not defined by the model.   We 
look at the initial conditions and we run the simulation to model how a normal lobule would react to chemical 
exposure.  To get the variability inherent in human beings, we generate different models.  The Virtual Liver model 
allows the evaluation of alternative hypotheses. 
To model a human 28-day repeated dose exposure, the Virtual Liver Framework Consortium takes the 
approach of simulating the concentration of the chemical in liver cells using in vitro clearance and partitioning, 
simulating molecular, cellular and tissue responses to chemicals using ToxCast
TM
 in vitro assays, and estimating the 
hepatic response at 28-days using in silico modeling.  The specific parameters were derived using in vivo data 
adjusted by applying molecular logic informed by pathway knowledge.  The success of this approach depends on a 
systematic approach to compiling information from multiple sources; for example, approximately 200 papers 
describing phenobarbital toxicity were used to link molecular events into a plausible pathway hypothesis.  
In the question-and-answer following this paper, it was noted that AOPs are dose- and time-dependent; 
accounting for context is critical and connecting the dots must be done in a careful way, for example, based on 
Bradford Hill Criteria.  It was also pointed out dose-response is important in discriminating between different possible 
outcomes for the same chemical.  It is important to dig more deeply into the actual perturbation that leads to the 
toxicity.   The ‘omics technologies are capable of providing enormous amounts of data; however, the idea that more 
information must surely be better is tempered by consideration of signal-to-noise; knowing what information is 
relevant is critical.
9
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6.7 An Integrated Predictive Platform for DILI:  Combining in silico and in vitro methods to predict toxicity 
mechanisms in vivo - Kas Subramanian 
The approach of Strand Life Science’s Virtual Liver project is to build a stable, normal liver model  in silico (Strand 
has developed a rat version and is working on a human version).  In vitro assays measure the effect of a 
drug/metabolite at certain points in the system; they do not measure toxic chemical endpoints.  Prediction of 
toxicity is a combination of assays and computational models. 
 The idea is to reveal critical pathways and mechanisms of toxicity.  The utility of the model is to aid 
drug design; to maintain potency while minimizing toxicity.  The model is not is a database of interactions, and it 
is not a QSAR model. The virtual liver consists of processes, pathways, etc., that are quantitatively linked and 
allows one to run simulations, make predictions and develop insights into the toxicity process.  It is a model of 
biology; it is not “trained” using existing drugs or chemicals, and therefore is not limited by a chemical space (but 
rather is limited by our knowledge of biological space).  The virtual liver can model hepatotoxicity, metabolic 
disease, and cardiovascular disease. 
 The Virtual Liver project takes a top-down, integrated approach, similar to completing a jigsaw puzzle 
by piecing together the outline first: the boundary is the phenotype.  Experimental, human, gene expression and 
other kinds of data start filling in the center part of the puzzle, and the gaps are filled by hypothesis.  The process 
involves identifying key processes and writing a series of differential equations to model each state of the 
network.  This approach does not look for initiating events.  
 To validate the model, the first question is to ask whether it represents normal physiology.  If it does, 
then additional simulations test whether the model correctly predicts the effects of environmental insults (drugs or 
toxicants) or genetic mutations (the model is for acute injury, and does not account for changes over time that are 
                                                          
9
 Dr. Shah recommends reading The Signal and the Noise: Why So Many Predictions Fail-but Some Don't by Nate Silver (Penguin 
Press, 2012). 
ALTEX Online first  





involved in chronic insults).   Over 40 compounds have been tested in the model with reasonable predictive 
accuracy and mechanistic insight.
10
  An important aspect of the model is the ability to look at combinatorial 
effects of different networks; if you don’t take into account what the effects other pathways have on a particular 
pathway you might be missing something.  This model also has the capacity to superimpose the effects of diet, 
diabetes, etc., and can provide insights into idiosyncratic events. 
 The project was started in 2005.  Over the last two years many of the assays have been identified and 
optimized and are ready to test a batch of chemicals.  The project has had support from a grant from the World 
Bank and the Indian government’s department of biotechnology. 
 In discussion following this presentation, a questionner asked whether the model is changed when the 
predictions are not correct.  There could be two reasons for incorrect predictions: the available assays may not 
be capturing a key event (the Strand team estimates only about 60% of the necessary assays are in place), or 
the model is predicting something other than is being observed; in that case, the modelershave to ask if they 
have the biology right or need to go back and add more information.  The idea was raised that the model is 
essentially asking “at what point will the airplane crash?”  You want to be able to ask your model what kinds of 
things go wrong and where, and verify that with experimental data.  Subramanian’s team has begun a step-by-
step analysis for some chemicals (e.g. troglitazone), but have not yet performed a systematic approach to this 
question.   
 
6.8 In Vitro Approaches for Predicting Liver Specific Toxicity – Colleen Toole 
Predicting liver toxicity in vitro requires understanding hepatic physiology and function as well as things like route of 
exposure and blood flow.  It also requires the proper tools, including cell models that represent key processes and 
biomarkers that monitor liver functions; pathways are critical to tying these together.  Orally administered chemicals 
may be metabolized by the gut prior to arriving in the liver; chemicals that are administered by other routes may also 
be modified before entering the liver.  In addition, CYP metabolism plays a large role in liver toxicity- any in vitro 
assessment methods need to take all of these things into account.   
Chemical disruption of normal liver function can – but does not necessarily - lead to adverse effects.  
Chemicals that disrupt glycolysis or oxidative metabolism are among those that can cause liver toxicity.  For example, 
the mitochondria in hepatocytes are the most sensitive targets for rotenone.   
Modification by CYP enzymes can either activate or deactivate a chemical’s capacity for hepatotoxicity.  For 
example, in the case of diclofenac, a non-steroidal anti-inflammatory, there were a couple hundred cases of liver 
failure resulting in death.  It only occurred when diclofenac reached a certain level and is thought to be caused by a 
reactive intermediate metabolized via CYP3A4 metabolism.  Another intermediate produced via CYP2C9 metabolism 
is not as reactive. A drug (co-administered) that would inhibit CYP3A4 would reduce the toxicity of diclofenac.   
Most drugs that inhibit the bile salt export pump (BSEP; in the canicular membrane) with an IC50 value < 25 
μM are associated with liver toxicity (Kis et al., 2012).  Inhibition of bile flow can lead to chronic liver toxicity.   
Selection of an appropriate cell model is important when organ specific toxicity is the goal: primary 
hepatocytes from the species of interest are preferred – e.g., dogs, humans.  Questions to ask of the model include 
whether it is capable of intrinsic clearance, metabolism, transport and/or polarization (Wilkening & Bader, 2003)?  
Primary hepatocytes grown in sandwich cultures (e.g. a collagen Matrigel sandwich) that can form canicular 
membranes begin to look like true hepatocytes and address these requirements fairly well.  Monitoring multiple 
endpoints of general cell health as well as liver-specific functions provides the most accurate prediction of liver 
toxicity.  When exposure is by a route other than oral, an additional cell type that can mimic the route-dependent 
metabolism is needed; CeeTox sets up multiple cell models for determining organ specific toxicity. 
In summary, in vitro models can identify liver specific toxicity; cell models should be species-specific and 
should possess key functions of the liver; in vitro data must consider pharmacokinetic data; and in vitro endpoints 
should measure both liver specific function and general cell health. 
Among the points raised in discussion of this presentation were: (1) assessing the metabolic competence of 
all of these cell systems is critical, and (2) how do you deal with metabolites created in one tissue that circulate to 
another?  Generally, metabolites that are in the liver are excreted through the bile; where it becomes an issue is 
when the liver is failing so that physiologic steps of pharmacologic clearance are not happening properly. The 
metabolites of some chemicals (e.g. aromatic amines) are metabolized by the liver and can affect other organs (e.g. 
kidney). 
 
6.9 Description of prototype modes-of-action related to repeated dose toxicity: overview of fibrosis and 
steatosis pathways --‐   Brigitte Landesmann 
In the context of SEURAT-1, prototype MoAs related to repeated dose liver toxicity have been developed.  The 
working definition of MoA used for this work was taken from Boobis et al.(2008): “the sequence of key events 
starting with the interaction of an agent with a target cell, through functional and anatomical changes resulting in 
cancer or other adverse health effects.”   
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A stepwise approach according to OECD guidance for AOP development has been applied: the first steps 
were the selection of the adverse outcome and the molecular initiating event, the two anchors that also specify the 
AOP, followed by the study of the relevant physiology that is underpinning the process. This step is crucial because 
AOP development requires knowledge of the underlying biological mechanisms to understand how sufficient 
perturbation of normal function by a chemical may result in dysregulation and, ultimately, toxicity.  Next, the 
intermediate events were identified and subsequently the elaborated pathway was graphically presented.  Then the 
scientific evidence underlying the AOP had to be evaluated and reported by assessing the weight-of-evidence 
according the Bradford Hill criteria.  
The selection of liver fibrosis and liver steatosis as AOs was due to the fact that they typically result from 
chronic injury and accord with SEURAT-1 research activities.  Protein alkylation was chosen as the MIE for fibrosis 
because it is common to the two SEURAT reference chemicals for liver fibrosis (allyl alcohol and carbon 
tetrachloride).  Nuclear receptor (NR) binding was chosen as the MIE for steatosis, because endocrine disrupting 
chemicals (EDCs) also act through interaction with NRs and there is globally increased attention in this area in 
relation to EDCs. Liver X receptor (LXR) was chosen from the six relevant NRs because the LXR agonist 
T0901317 is one of SEURAT’s reference chemicals for liver steatosis.  A systematic literature search was 
undertaken with emphasis on key studies and review papers and consecutive analysis according to different levels 
of biological organization.  This process is time-consuming and expertise is needed to choose the relevant level of 
detail, as well as to resolve differences between studies (e.g,. species, cell model, concentrations).  A diagram 
delineating the pathway was created, and the pathway was evaluated using Bradford Hill criteria for a weight-of-
evidence (WoE) approach, including an evaluation of the number and quality of the available studies, the coherence 
and consistency between the findings, the biological plausibility, and the relevance of the used models and 
consideration of alternative explanations.  Finally, the pathway development was reported according to OECD 
guidance. 
Some problematic issues important to consider when developing MoAs are: the level of detail in data 
collection; linearity vs. feedback and feed-forward loops and complex inter-relations; how to identify key events; 
how to incorporate quantitative evaluation (dose-response relationships) and temporal relationships.   
In the liver fibrosis MoA being described here, the MIE is alkylation caused by allyl alcohol and carbon 
tetrachloride and the supporting evidence was judged to be “well established” (noting that this is not the only 
possible MIE – any insult that results in cell death can initiate fibrosis).  The intermediate events identified were 
hepatocyte injury causing necrosis or apoptosis (with “very strong” scientific evidence), activation of hepatic 
macrophages (Kupffer cells)(very strong),  TGF-β1 expression (very strong), stellate cell activation (very strong), 
collagen accumulation (very strong), oxidative stress (strong), and chronic inflammation (very strong).  Many 
organs in addition to liver are subject to fibrosis (e.g. lung, kidney, heart, skin, pancreas), and there is some 
evidence for common preserved pathways across species. 
Likewise, steatosis was described as in the introduction, with the MIE being Liver X Receptor (LXR) 
activation.  Intermediate events at the molecular level include: auto-regulation of the LXRα (up regulation, positive 
feedback); increase in expression and activity of the carbohydrate response element binding protein (ChREBP); 
increase in expression of the sterol response element binding protein 1c (SREBP-1c) from LXR activation and from 
the ChREBP; induction of lipogenic enymes from the SREBP-1c, up-regulation of the free fatty acid uptake 
transporter FAT/CD36, induction of the fatty acid synthase (FAS) and induction of the stearoyl-CoA desaturase 1 
(SCD1) These intermediate events lead to de novo synthesis of fatty acids and triglycerides and fat influx from the 
peripheral tissues to liver.   
Intermediate events at the organelle level include mitochondrial toxicity attributed to increased lipid 
peroxidation and reactive oxygen species overproduction and endoplasmic reticulum stress as a consequence of 
increased hepatic lipids.  Intermediate events at the cellular level include cell burst (fat accumulation), cell cycle arrest 
(followed by failure of compensatory cell division) and necrosis and/or apoptosis (resulting from fat accumulation 
causing oxidative stress, energy depletion, cytokine release, and /or mitochondrial toxicity).  Intermediate events at 
the tissue level include fat accumulation (either microvesicular or macrovesicular) and finally liver steatosis (when 
liver fat reaches greater than 5 – 10 % of the liver by weight). 
The elaborated pathway was evaluated according to OECD guidance: 1) concordance of dose-response 
relationships: no available dose-response curves but sporadic numerical data; 2) temporal concordance among the 
key events and adverse outcome: the sequence of the events is in strong agreement; 3) strength, consistency, and 
specificity of association of adverse outcome and initiating event: strong and consistent association but not specific; 
4) relevance: LXR expression and all the other elements are considered adequately conserved from rodents to 
humans; 5) uncertainties, inconsistencies and data gaps: there are differences in LXR expression between cell lines; 
the MoA could be affected by ethnicity and the life stage of the individual; there are possible effects by factors related 
to the formation of steatosis including trends in adipose tissue (AT) deposition, total body fat, and visceral and 
subcutaneous adipose tissue (which vary among different life stages, sexes and ethnicity).  The biological plausibility, 
coherence, and consistency of the experimental evidence and the existence of alternative mechanisms have not yet 
been described.  
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7 Discussion: Pathway approaches to liver toxicity 
 
Discussion for this session was led by Imran Shah, following a set of questions prepared by the organizing 
committee.  The questions included: how generalizable is the pathways in terms of chemical space; how central is the 
particular described-MIE to the observed adverse outcome; what uses can be made of the pathway at its current level 
of completeness; and what elements are missing that are necessary for other applications.  
 
7.1. The fibrosis pathway 
While fibrosis is a general response that can be caused by many and varied MIE, this particular MIE may be fairly 
specific to the chosen chemicals (allyl alcohol and carbon tetrachloride).  There are several other MIEs leading to 
fibrosis, for example, alcohol (ethyl alcohol) is a major cause of fibrosis but is not a protein binder and is not included 
in this MIE.  In general, initial key events are chemical-specific, whereas later intermediate events are disease-
specific.  If apoptosis is a key event in fibrosis, then any MIEs that lead to apoptosis should also lead to fibrosis, but in 
fact, not all chemicals that cause apoptosis lead to fibrosis.  For this particular MIE, the rate of apoptosis is the 
important factor; therefore, what is really needed is the dose and temporal data.  To inform whether a chemical will 
cause liver fibrosis in contrast to other apoptosis-related adverse outcomes, it must be clear that the chemical of 
interest actually reaches the liver (ADME information could be integrated as part of the AOP).  Further 
characterization of intermediate events is needed and is necessary for identification of key events.  
It was agreed that this MIE is fairly well described and can be used for read-across, and that liver fibrosis is 
a good anchor for an endpoint because it relates to something that can be looked at in a relevant way (that is, the 
endpoint can be observed in both an animal model and related clinically).  Participants agreed that aiming for a 
perfectly-described AOP is neither possible nor necessary.  What is needed is sufficient information to make a 
particular decision.  AOPs are plausible abstractions that are refined in increments, but even less-sophisticated or 
less-refined AOPs can be useful in the decision-making process. 
The current fibrosis AOP as described is a useful starting point for capturing relevant intermediate events.  It 
allows investigators to do targeted testing, determine missing information, and then develop a series of hypotheses 
that can be tested within a limited amount of time.  Also important for the utility of this AOP is to resist thinking of 




The most important aspects of proving causal relationships according to the Bradford Hill criteria are 
temporal and dose-response relationships.  Temporality has been shown for the main intermediate events in this 
(fibrosis) MoA, but the dose-response data are lacking (Landesmann, 2012).  In addition, it will be important to 
compare to chemicals which cause alkylation, but that do not cause fibrosis, as this could help distinguish the 
specificity of the MIE and could help in making quantitative distinctions in thresholds that result in adaptation versus 
adversity. 
 
7.2. The steatosis pathway 
For the adverse outcome of steatosis, there are potentially several competing pathways, including LXR and multiple 
nuclear receptor-dependent pathways.  This MIE is likely only one of several that can lead to steatosis.  For example, 
toxicogenomic studies have been done to identify genes that are specifically activated by steatosis,  inc lud ing 
s tud ies  testing the effects of agents in microarrays followed by validation by PCR.  In these studies, CD36 was 
not one of the genes identified, so CD36 up-regulation may be specific for this chemical and may indicate that this 
MIE is not generalizable to other chemicals; however, the link between CD36 and steatosis was only recently 
recognized, so future studies may discover a broader applicability  
In addition, there are two different forms of steatosis, micro- and macrovesicular.  Microvesicular steatosis 
is very serious, related to beta-oxidation and mitochondrial toxicity, and does not necessarily progress to 
macrovesicular.  Macrovesicular steatosis is associated with many physiological syndromes, including alcohol 
consumption, and involves suppression of fatty acid/triglyceride efflux.  There are some differences in the 
composition of the vesicles in micro and macro (fatty acid vs triglyceride) Perhaps this AOP should be split into 
micro/macro steatosis for the tissue endpoint.  A steatosis expert might be needed to make some of these 
distinctions. 
The described pathway is a good start for the biological description of steatosis, but may be too narrowly 
applicable and insufficiently developed to be used in its current form.   
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advanced fibrosis was found to be around 2.8% in a French general population aged 40 years or older. Several independent risk 
factors have been identified – but early fibrosis is still hard to detect via non-invasive biomarkers (Poynard et al. BMC 
Gastroenterology 2010, 10:40). 
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8 Using pathway-based approaches to inform decision-making  
 
This discussion was facilitated by Mel Andersen, and addressed issues such as relating in vitro observations to in 
vivo adversity, how to identify assays that can model intermediate or key events, and how to make sure all 
mechanisms of liver toxicity are sufficiently covered, including MIEs and AOs for different chemical categories.  
 To use pathways as a construct to inform decisions, an initial step is to describe the causal linkages 
between the intermediate events (a “qualitative AOP”), and then begin to quantify these relationships.  This is an 
iterative process.  As noted earlier, different uses of AOPs require different levels of certainty and quantification.  For 
risk assessment, quantification is necessary: how much do you need to perturb a given step in the pathway to 
provoke the next step?  To differentiate adverse conditions from perturbations within homeostatic bounds, thresholds 
will need to be defined to separate, for example, endocrine disruptors from non-endocrine disruptors.  Once the 
relationships have been quantified, it may be possible to identify an ‘upstream event’ as a quantitative point of 
departure for a downstream adverse outcome.  
 Discussants pointed out that adversity is a matter of degree: for example,  clinically elevated 
enzymes are not considered alarming until bilirubin levels rise (at which point it is indeed serious).  An AOP needs to 
reflect a grading system of severity that maps to existing clinical guidelines. 
 This process is resource-intensive, so we want to first focus resources on investigating those 
endpoints that are legislatively mandated and are actually driving the risk assessments.   
 It is likely that different assays are needed to build the pathways than are needed in integrated testing 
strategies using the pathways to evaluate chemicals.  A related question is what assays to use to quantify the 
relationships.  For example, ER binding and gene expression are two key events in the estrogen receptor-mediated 
reproductive impairment AOP: so now we need to do directed/targeted testing to make the quantitative links between 
them. 
 We are just beginning to get glimpses of the complex system that leads to different forms of liver toxicity, so 
imposing linearity on the AOP in these early stages makes it more manageable.  We must start small and accept 
some uncertainty, knowing that we will be adding information and complexity step-wise until all observations are 
accounted for.  Understanding the full context of an AOP is a little bit like moving traffic: there may be one well-
established route to our destination, but in certain events – an accident, for example – we want to know the alternate 
routes to that destination.  In fact, a vision for the future would be to build a collection of fibrosis pathways, for 
example, with different MIEs. Then someone can go to the Toolbox, ask which pathways lead to fibrosis, and use that 
information in a diagnostic context, to identify target tests for an individual exhibiting fibrosis.  This vision underscores 
the importance of creating a centralized knowledge base.  As one participant noted, a strength of the AOP approach 




9 Concluding remarks 
 
The participants in this workshop discussed the state-of-the-art in adverse outcome pathway development and 
focused discussion on two pathways in particular, the prototype modes-of-action for liver fibrosis and steatosis 
developed by the European Commission Joint Research Centre. There was consensus that the AOP concept is 
extremely useful for organizing information at all levels of biological organization (from the molecular, cellular, tissue, 
to the population-level) and across the spectrum of biological information (chemistry, bioinformatics, ‘omics, histology, 
guideline animal data).  The OECD definition of the AOP as a linear portion of a biological network from a single 
molecular initiating event (MIE) to a single adverse outcome (AO) is useful theoretically as a simplifying concept, but 
may be too limiting to be practical; some AOPs may necessarily involve branching.  For many participants, the terms 
Mode-of-Action (MOA) and AOP were synonymous; for some, the AOP encompasses the MOA, which is the 
upstream portion of the AOP, from the MIE through to resulting cellular and tissue changes.  There was consensus 
that the quality assurance methodologies described in OECD guidance (e.g., to assess data quality, causal 
relationships and completeness of the AOP) were appropriate and essential.  The confidence and completeness of 
an AOP will determine its usefulness: less complete AOPs can be useful for chemical categorization and prioritization 
of chemicals for further testing while AOPs with high confidence and quantitative understanding of the links between 
events are necessary if they are to be used to inform risk assessment.  There was also consensus that the best way 
to progress is to develop case studies; indeed, several working groups are taking this approach.  In addition, focusing 
the more theoretical conversation about AOP development on a specific AOP is extremely helpful; for example, many 
general concepts were discussed focusing on the fibrosis AOP.  
Liver toxicity is an appropriate subject for AOP case studies as it is central to acute, subchronic and chronic 
chemical exposure, whether it be during repeated exposure to environmental chemicals or to drugs, where liver 
toxicity is a leading cause of removal from the market.  Drug-induced liver injury (DILI) is rare, making it hard to detect 
in clinical trials, but often fatal.  DILI can also be highly dependent on the patient’s own genetic makeup and 
physiological condition – underscoring the need for a better understanding of the underlying biology to better predict 
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the occurrence and outcomes.  While there are described diagnostic markers for DILI, these are not specific, and 
more importantly, are not predictive of future occurrence.  Understanding liver toxicity requires an in-depth 
understanding of normal liver function as well as the pathways perturbations that occur during toxicity.  Pathway-
based approaches to liver toxicity and DILI are important for identifying predictive biomarkers.   
The liver fibrosis MoA presented by the JRC was delineated using information from exposure to allyl alcohol 
and carbon tetrachloride, and therefore the MIE is protein alkylation.  While this MIE is specific for these two 
chemicals and is not applicable to other toxicants (e.g., ethanol), experience with and information about these other 
well-studied chemicals can inform general understanding of liver biology and fibrosis MOAs.  Conversely, it is 
important to begin with case studies, and build pathways out from these well-described prototypes. 
Steatosis (fatty liver) may be caused by several MIEs, one of which is interference with the array of 
nuclear receptors involved in homeostasis of fatty acid metabolism; the MOA discussed involved activation of the 
Liver X receptor (LXR) as the MIE.  Binding to LXR causes an induction of transcription factors leading to de novo 
fatty acid and triglyceride synthesis as well as an influx of fat from peripheral tissues to the liver.  Fatty acid 
accumulation can be protective and its appearance in humans is not necessarily cause for alarm; however, its 
appearance in animal studies during drug development may stop further development.  Micro- and macrovesicular 
steatosis are separate clinical entities:  microvesicular steatosis is more serious and indicates a problem with 
mitochondrial beta-oxidation and breakdown of fatty acids which affects the production of ATP.  Macrovesicular 
steatosis is associated with many conditions, including alcohol-suppression of fatty acid/triglyceride efflux.  There 
are differences in the composition of the vesicles in micro and macro (fatty acid vs. triglyceride).  It was suggested 
that this AOP should be split into two – one for micro- and another for macrovesicular steatosis.   
Bioinformatics and modeling approaches are being used to identify predictive markers or signatures for liver 
toxicity; these data can also inform pathway development and the two approaches can be used to support predictive 
modeling in complementary ways: bioinformatics can help delineate MIEs and upstream intermediate pathway 
events, and formal pathway descriptions can be used to support hypothesis-based testing that can be used to 
“validate” both the predictive markers and signatures, as well as the pathway assumptions.  Bioinformatics and 
modeling approaches can also be used to incorporate the influences of genetic variability on normal and perturbed 
pathways.   To fully inform pathway development, it is also essential to incorporate the knowledge from histologists 
and clinicians familiar with the biological outcomes at the tissue and individual levels.  In the case of DILI, there are 
also large human databases that contain information that can be used to inform idiosyncratic factors.   
Some important considerations for the future of AOP development in general and liver AOPs in particular 
that were discussed included: accounting for context - AOPs are species, tissue, timing and dose-dependent; 
consideration of metabolism, both before entering the liver and within the liver; the fact that more information isn’t 
always better - a consideration of signal-to-noise and knowing what information is relevant is critical;   identification of 
appropriate tools to test integrated strategies including appropriate cell types and tissue constructs; incorporation of 
severity – prediction when the “tipping-point” of adversity has been reached (quantification of the relationships 
between intermediate effects is necessary); appropriate design of assays to inform the quantitative relationships 
between intermediate events; the importance of a centralized and accessible knowledge base.  At the conclusion of 
the workshop, participants were asked to share what they saw as the most salient “take-away” message(s) from the 
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Table 1: Final Thoughts 
Development 
AOPs should be generic and applicable to chemically diverse compounds that induce a certain type of 
toxicity.  Moreover, the relevance of AOPs should be substantiated by human-relevant clinical data as it 
is not a simple summary of mechanisms described in scientific literature. 
AOPs express incomplete views of the sequential phenomena involved in linking exposure to outcome. 
AOPs do not imply linear relationships between phenomena - the nonlinearity (feedback) is implicit. 
Perspective on key events will differ according to who is assessing. 
MIEs: unlikely that one MIE leads to one IE and one AO, however, it provides a starting point for a more 
complex explanation 
In vitro and in silico approaches provide useful fingerprints of homeostasis and how it can be altered or 
disrupted by changing one or several parameters and which pathways could be targeted 
Need for language agreement- shared terminology. 
It is helpful to have a conversation between individuals from various backgrounds and learning their 
needs and perspectives, especially in a regulatory environment 
Excellent to discuss a prototype pathway (fibrosis) as it makes the discussion more real.  Hopefully this 
can continue to the phase of “how do in vitro models fit into this AOP?” 
Important to have medical professionals in the discussion on “adversity” – I really believe it is truly 
adverse events in humans that the AOP framework can help us with 
Use 
AOPs are serving to facilitate communication of information on toxicology to regulators and 
governmental agencies, primarily in the EU.  AOPs explicitly display our understanding of the 
relationship of specific processes (steps) to effects that serve as regulatory endpoints.  More 
widespread use of these AOPs will be useful in designing targeted testing strategies, better short term 
test methods, and support initiatives that will eliminate/reduce reliance on animal testing for decision 
making. 
The phrase “designed for purpose” is a perfect description of a use of AOPs - to help design targeted 
testing rather than test a whole set of assays likely to be unrelated to the hazard associated with your 
chemical 
'Form follows function' - The structure/design of the AOP is determined by its application. 
The use of AOP should be clearly articulated, since experimental validation will depend on intended 
usage 
AOP does not necessarily reduce uncertainty in risk assessment, but does inform it,  
End-use for the AOP needs to be defined as it relates to the type and nature (quantitative vs. 
qualitative) of information. 
Needs for drugs and chemicals are different: for drugs are looking for a needle in a haystack – for 
chemicals need only to be sure for 95% of cases - and what may seem not certain enough for clinical 
trials in fact be sufficient for estimating risk of chemicals. 
An “established AOP” can be qualitative, based on a minimal set of data (causal linkages between key 
events established) – depends on the use. 
How different people/groups will/can use AOPs in different ways is exciting and perhaps we could be 
more explicit about this. 
Next steps 
AOP concept is established - next step is to make use of the tools and create data. 
Need activity on various fronts to encourage flexible and widely accepted frameworks for incorporation 
of AOP into regulatory context. 
Examples of AOPs are key to progress the concept. 
Populate AOPs with DATA – move from concept to application. 
How do we implement the concept of “necessary but not sufficient” into AOP development and 
acceptance? 
Identification of thresholds is needed - the importance of the in vitro dose, (in the medium/intracellular) 
will be important in identifying a true threshold. 
Multiple agencies with similar agendas must coordinate their efforts. 
Quantification is critical – is where the rubber meets the road. 
The shift from theoretical discussion to attempts to find a practical application yet still remain flexible to 
individuals’ needs and applications is critical to further the discussion. 
A very stratified and transparent method for central data collection, assay development and AOP 
publication needs to be specifically identified and advertised. 
ALTEX Online first  
published February 17, 2014 
http://dx.doi.org/10.14573/altex.1401281 
 
22 
 
 
 
